SUMMARY Anticomplement Immunofluorescence was used for antibody titration against varicellazoster virus (VZV) in 43 patients with peripheral facial palsy. Nine of 31 patients (29%) with Bell's palsy and eight of 12 patients (75%) with Ramsey-Hunt syndrome had anticomplement immunofluorescence antibody titres of > 1/10. On the other hand, none of 14 patients with herpes simplex virus (HSV) infection and 51 healthy adults showed anticomplement immunofluorescence antibody titres of > 1/10. The anticomplement immunofluorescence antibody titre in two patients with Ramsey-Hunt syndrome increased later and decreased sooner than the indirect immunofluorescence antibody titre, becoming undetectable at 66 and 104 days, respectively, after onset of the disease. There was no cross reaction between anti-VZV and anti-HSV antibodies in the patients who showed a positive antibody rise for VZV. As the acute stage of VZV infection is obscure in the patients with peripheral facial palsy without herpes the screening of anticomplement immunofluorescence antibody to VZV at titres > 1/10 may be useful for the diagnosis of VZV infection in patients with peripheral facial palsy.
The direct cause of Bell's palsy (idiopathic peripheral facial palsy) is unknown. Some part of the disease, however, is considered to be caused by varicellazoster virus (VZV) infection.1`6 As there is no evidence of herpetic eruption, isolation of VZV from patients with Bell's palsy is very difficult. Although serum antibody titration for VZV is useful for virological diagnosis, it is necessary to obtain proper paired (acute and convalescent) sera from the patients to detect any clinically important rise in antibody.
In a previous paper we reported that VZV anticomplement immunofluorescence using paired sera from patients with varicella or herpes zoster showed a specific response between the acute and convalescent stages of the diseases. 7 We observed, however, that the sensitivity of anticomplement immunofluorescence was somewhat less than membrane immunofluorescence and indirect immunofluorescence. 7 In that study we also titrated VZV antibody using anticomplement immunofluorescence in healthy adults and found that their antibody titre was always less than 1/10. Thus we concluded that among the population aged more than 20 years people who Accepted for publication 29 May 1986 had anticomplement immunofluorescence antibody for VZV with a titre > 1/10 had probably had a recent VZV infection. In the present paper we report the incidence of anticomplement immunofluorescence antibody in the patients with peripheral facial palsy and matched controls.
Material and methods

VIRUS STRAIN AND TISSUE CULTURE
The Hirai strain of VZV, which was isolated from a patient with herpes zoster was routinely used in the experiment. The details of propagation of this strain in tissue culture cells have been reported previously.7
The Kos strain of herpes simplex virus (HSV) type 1 was used for the preparation of anticomplement immunofluorescence antigen. A human embryo fibroblast strain was subcultured with Eagle's minimal essential medium containing 10% new born calf serum, 100 pg/ml of streptomycin, and 100 units/ml of penicillin. For the virus infection the medium was changed to minimal essential medium containing 2% fetal calf serum figure) . Table 2 shows the results of VZV antibody titrations of 18 paired sera To show any cross reactions between anti-HSV antibody and VZV antigen or anti-VZV antibody and HSV antigen paired sera from eight patients with VZV infection were examined for both anti-VZV and anti-HSV antibodies using anticomplement immunofluorescence. Table 3 shpws that none of the paired sera showed a rise in antibody titre against HSV, although all of them showed an appreciable rise in antibody against VZV. Moreover, none of the eight sera, which possessed anticomplement immunofluorescence antibody for VZV of titres between 1/10 and 1/160, possessed antibody to HSV at a titre of more than 1/10. Only one serum, with an anti-VZV antibody of 1/640, had an anti-HSV antibody of 1/10.
Discussion
In the previous paper we reported a lower incidence of anticomplement immunofluorescence antibody than membrane immunofluorescence antibody in a population of healthy subjects. Although these workers took the lowest titre for detectable anticomplement immunofluorescence antibody (1/5), while our minimum positive titre was 1/10, there is still some discrepancy between their results and ours. Their titration method had two steps, the first being incubation of antigen with -antiserum and the second incubation with complement. By comparison, our method is one step-that is, simultaneous incubation of antigen, antibody, and complement. One of the authors commenting on our data suggested that low antibody titres may have been due to the anticomplementary effect of serum during the incubation. 8 We tested all sera, however, for anticomplementary activity using a hemolysin and sheep erythrocyte system, and no anticomplementary activity was observed. We also determined an optimum dilution of GP-C' for the anticomplement immunofluorescence using a chessboard titration of GP-C' against antiserium. As previously reported our anticomplement immunofluorescence method is less sensitive than membrane immunofluorescence or indirect immunofluorescence, but this insensitivity gives a negative incidence of anticomplement immunofluorescence antibody in a healthy adult population and also facilitates a diagnosis of VZV infection in adults with Bell's palsy. We also reported in the previous paper that anticomplement immunofluorescence antibody rose in patients with VZV infections but that no heterotypic reactions to HSV and human cyto*iegalovirus antigens were observed Shigeta, Baba, Ogata, Nozaki, Okuaki, Nakamura in those patients. 7 We have confirmed these observations in the present study and also that no anticomplement immunofluorescence antibody for VZV was detected in patients with HSV infections (HSV stomatitis, herpes labialis, HSV encephalitis), and that no anticomplement immunofluorescence antibody rise to HSV was observed in paired sera from patients with VZV infection. In particular, six patients with peripheral facial palsy who showed an antibody rise to VZV did not respond to HSV at all. Our results may not necessarily eliminate the possibility of HSV infection as a cause of Bell's palsy. The negative incidence of anticomplement immunofluorescence antibody for VZV in the control group and positive incidence in 29% of the adult patients with Bell's palsy, however, indicated that these patients had had a VZV infection within 60 to 100 days before the serum specimen was taken (figure). The incidence of VZV infection in Bell's palsy is similar to the results obtained by Tomita et al, in which they titrated complement fixing antibody for VZV in paired sera and (25%) of 44 cases showed increased antibody titre.3 A lower incidence of VZV infection in Bell's palsy, however, was reported by other workers, and nine of 133 cases (68%),5 three of 33 cases (9.1 %),2 nine of 84 cases (10-7%)4 of Bell's palsy were diagnosed virologically as VZV infections. Uncertainty over the time of the acute stage of VZV infection in the patients with peripheral facial palsy without cutaneous herpes may show as a lower incidence of antibody rise using the indirect immunofluorescence method in which antibody titre increases promptly after infection. Anticomplement immunofluorescence antibody titration for VZV antibody in paired sera from patients with Bell's palsy was also as likely as with the indirect immunofluorescence method to give positive results if the acute sera were taken early. 46 Anticomplement immunofluorescence titration for VZV antibody using single or multiple sera from patients with Bell's palsy and setting a titre of positivity at 1/10 is a useful tool for diagnosing VZV infection in this aetiologically obscure disease.
